Multiple Myeloma | Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences

Featuring an interview with Dr Joseph Mikhael, including the following topics:

• Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00)
• KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47)
• Subgroup analysis of patients with 1q21 and other cytogenetic abnormalities in the Phase III IKEMA and ICARIA-MM studies (15:12)
• Results with ciltacabtagene autoleucel among patients with relapsed/refractory (R/R) MM in the CARTITUDE-1 study (26:59)
• CARTITUDE-4 study: Ciltacabtagene autoleucel in earlier lines of treatment for patients with lenalidomide-refractory MM (34:56)
• KarMMa-3 trial: Idecabtagene vicleucel for patients with R/R MM (44:20)
• GPRC5D-targeted CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MM (49:09)
• Efficacy of teclistamab for R/R MM in the MajesTEC-1 trial (53:45)
• Efficacy of elranatamab for R/R MM in the MagnetisMM-3 trial (58:43)
• Efficacy of linvoseltamab for R/R MM in the LINKER-MM1 trial (1:02:01)
• Talquetamab for patients with R/R MM in the MonumenTAL-1 trial (1:04:16)
• Future directions in the first-line management of MM (1:06:03)
• Strategies to improve diversity and inclusion in clinical trials (1:10:53)

CME information and select publications